Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Nom du journal : Haematologica
Année : 2023
Volume : 108
Page de départ : 2774-2782
